Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04162756
Title Study of KTE-X19 for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18)
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Kite, A Gilead Company

mantle cell lymphoma


Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Stanford Cancer Institute Stanford California 94305 United States Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Henry-Joyce Cancer Clinic Nashville Tennessee 37232 United States Details
The University of TX MD Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from for the field